Merck obtained MK-6070 through its acquisition of Harpoon Therapeutics. “Expanding our oncology pipeline with a DLL3 T-cell engager further supports Daiichi Sankyo’s strategy to create new standards of care for patients with cancer worldwide,” said Ken Takeshita, MD, global head,...
About Premium Create free account Log inCreate a free Seeking Alpha account to access breaking news and valuable research tools »Create Free AccountSeeking Alpha - Power to Investors Power to Investors Follow us Download app Account Account Login Manage My Portfolio Privacy Crea...
TOKYO & RAHWAY, N.J., August 6, 2024 – Daiichi Sankyo (TSE: 4568) and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) (NYSE: MRK) have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug ...
About Premium Create free account Log inCreate a free Seeking Alpha account to access breaking news and valuable research tools »Create Free AccountSeeking Alpha - Power to Investors Power to Investors Follow us Download app Account Account Login Manage My Portfolio Privacy C...